Literature DB >> 6685454

Aztreonam, cefoperazone, and gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis in rabbits.

W D Kobasa, D Kaye.   

Abstract

The effectiveness of aztreonam, cefoperazone, and gentamicin alone and in combination was evaluated in Enterobacter aerogenes endocarditis in rabbits. The minimal inhibitory concentration/minimal bactericidal concentration ratios for E. aerogenes were as follows: aztreonam, 0.4/0.4 microgram/ml; cefoperazone, 0.8/0.8 microgram/ml; and gentamicin, 3.1/3.1 micrograms/ml. With an inoculum of 10(9) organisms per ml, aztreonam and cefoperazone were equivalent in reducing titers of E. aerogenes in broth, and both drugs demonstrated an increased rate of reduction when gentamicin was added; gentamicin alone was least effective. E. aerogenes endocarditis in rabbits was treated intramuscularly with aztreonam (60 mg/kg) every 6 h, with cefoperazone (60 mg/kg) every 6 h, with gentamicin (1.7 mg/kg) every 8 h, and with aztreonam plus gentamicin or cefoperazone plus gentamicin for 5 and 10 days, respectively. All of the therapeutic regimens were effective in reducing vegetation titers as compared with untreated controls. Aztreonam plus gentamicin was more effective than either aztreonam or gentamicin alone. Cefoperazone plus gentamicin was more effective than cefoperazone alone but was not more effective than gentamicin alone. Neither aztreonam and cefoperazone nor aztreonam and gentamicin differed significantly, but gentamicin was significantly more effective than cefoperazone. Aztreonam plus gentamicin did not differ significantly in effectiveness from cefoperazone plus gentamicin. Aztreonam gave a peak level of about 135 micrograms/ml and a half-life of 0.7 h. Cefoperazone gave a peak level of about 155 micrograms/ml and a half-life of 1.1 h. Gentamicin gave a peak level of 7.4 micrograms/ml and a half-life of 1.3 h.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6685454      PMCID: PMC185319          DOI: 10.1128/AAC.24.3.321

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Chemotherapy of experimental streptococcal endocarditis. I. Comparison of commonly recommended prophylactic regimens.

Authors:  D T Durack; R G Petersdorf
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

2.  Monobactams--monocyclic beta-lactam antibiotics produced by bacteria.

Authors:  R B Sykes; D P Bonner; K Bush; N H Georgopapadakou; J S Wells
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

3.  In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases.

Authors:  D M Livermore; J D Williams
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

Review 4.  Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977.

Authors:  P S Cohen; J H Maguire; L Weinstein
Journal:  Prog Cardiovasc Dis       Date:  1980 Jan-Feb       Impact factor: 8.194

5.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

6.  Antibiotic synergism in enterococcal endocarditis.

Authors:  J Carrizosa; D Kaye
Journal:  J Lab Clin Med       Date:  1976-07

7.  IN VITRO AND IN VIVO LABORATORY EVALUATION OF CEPHALOGLYCIN AND CEPHALORIDINE.

Authors:  W E WICK; W S BONIECE
Journal:  Appl Microbiol       Date:  1965-03

8.  High-pressure liquid chromatographic analysis of aztreonam in sera and urine.

Authors:  F G Pilkiewicz; B J Remsburg; S M Fisher; R B Sykes
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

9.  Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis.

Authors:  J A Boscia; O M Korzeniowski; R Snepar; W D Kobasa; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

10.  Cefoperazone treatment of experimental endocarditis.

Authors:  R A Snepar; J Carrizosa; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

  10 in total
  6 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.

Authors:  A Turcotte; M Simard; N J Morin; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

3.  Marvelous but Morbid: Infective endocarditis due to Serratia marcescens.

Authors:  Varun K Phadke; Jesse T Jacob
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2016-05

4.  Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis.

Authors:  J A Boscia; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

Review 5.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

6.  A rare cause of healthcare-associated infective endocarditis: Enterobacter cloacae.

Authors:  Omer Karasahin; Zıya Yildiz; Onur Unal; Umit Arslan
Journal:  IDCases       Date:  2018-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.